4,464 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Xponance Inc.

Xponance Inc. purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 4,464 shares of the company’s stock, valued at approximately $216,000.

Other hedge funds have also recently made changes to their positions in the company. Farallon Capital Management LLC grew its holdings in shares of Protagonist Therapeutics by 1.2% during the fourth quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company’s stock valued at $228,898,000 after buying an additional 69,000 shares during the last quarter. RTW Investments LP lifted its position in Protagonist Therapeutics by 1.3% during the fourth quarter. RTW Investments LP now owns 5,498,545 shares of the company’s stock valued at $212,244,000 after purchasing an additional 72,433 shares during the period. BVF Inc. IL raised its position in Protagonist Therapeutics by 2.7% in the fourth quarter. BVF Inc. IL now owns 1,900,015 shares of the company’s stock worth $73,341,000 after acquiring an additional 49,848 shares during the period. Price T Rowe Associates Inc. MD raised its position in Protagonist Therapeutics by 6.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company’s stock worth $53,758,000 after acquiring an additional 83,185 shares during the period. Finally, Deep Track Capital LP bought a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $38,600,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PTGX shares. Citigroup initiated coverage on shares of Protagonist Therapeutics in a report on Tuesday, June 17th. They issued a “buy” rating and a $72.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Wedbush reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, Wall Street Zen upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, June 8th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $66.10.

Protagonist Therapeutics Trading Down 1.7%

Shares of NASDAQ PTGX opened at $55.48 on Friday. The stock has a fifty day simple moving average of $51.29 and a two-hundred day simple moving average of $45.65. Protagonist Therapeutics, Inc. has a 1-year low of $32.50 and a 1-year high of $60.60. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of 73.97 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. The company had revenue of $28.32 million for the quarter, compared to analysts’ expectations of $30.44 million. Analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Activity

In other news, CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the sale, the chief financial officer owned 61,065 shares in the company, valued at $2,808,990. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Arturo Md Molina sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the completion of the sale, the insider directly owned 83,892 shares in the company, valued at $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.90% of the stock is owned by corporate insiders.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.